CONDITIONS WE TREAT
Cardiovascular disease involves complex upstream biological drivers including endothelial dysfunction, oxidative stress, chronic inflammation, and metabolic impairment. SynergyO3 investigates these root mechanisms — designing physician-supervised protocols to support vascular health alongside conventional cardiac care.
CLINICAL PRESENTATION
Cardiovascular conditions manifest across a wide spectrum of presentations. Many patients with established diagnoses continue to experience functional limitations despite conventional management. Individual results vary — Dr. Volpp evaluates each patient's complete picture.
SynergyO3 works with patients managing coronary artery disease, hypertension, peripheral arterial disease, heart failure (stable), atrial fibrillation, post-cardiac-event recovery, and metabolic syndrome with cardiovascular risk. We complement (not replace) cardiologic care.
Relevant findings may include elevated CRP, homocysteine, oxidized LDL, Lp(a), fibrinogen, and NT-proBNP; reduced VO₂ max; endothelial dysfunction on flow-mediated dilation testing; mitochondrial markers; and elevated oxidative stress biomarkers.
COMMONLY OVERLAPPING CONDITIONS
CLINICAL EDUCATION
Cardiovascular disease is fundamentally a disease of inflammation and oxidative stress. Endothelial injury, lipid oxidation, and chronic low-grade inflammation drive atherosclerotic progression, vascular stiffening, and cardiac remodeling. Mitochondrial dysfunction in cardiac muscle further impairs contractile function and energy production.
Nitric oxide (NO) produced by endothelial cells regulates vascular tone and inhibits platelet aggregation. Oxidative stress consumes NO, impairing vasodilation, promoting inflammation, and accelerating atherosclerotic plaque formation and progression.
Elevated CRP, IL-6, and TNF-α drive macrophage activation, foam cell formation, and plaque instability. Chronic low-grade inflammation — linked to metabolic syndrome, gut dysbiosis, and oxidative burden — is now recognized as a primary cardiovascular risk driver.
The heart is the most mitochondria-dense organ in the body. Oxidative damage to cardiac mitochondria impairs ATP production, reduces contractile efficiency, and accelerates heart failure progression. Supporting mitochondrial health is a key upstream target.
KEY STATISTICS
Comprehensive intake, targeted labs, and biomarker assessment to map biological drivers.
Physician-designed sequenced protocol combining EBOO, HOCATT, and IV nutrients.
Follow-up labs, functional benchmarks, and protocol refinement based on response.
ROOT CAUSE INVESTIGATION
Dr. Volpp evaluates each patient's complete picture — identifying which biological mechanisms are most active — before any protocol is designed. Individual results vary.
Native LDL is not inherently atherogenic — oxidized LDL is. Oxidative stress converts LDL to an inflammatory trigger, activating macrophages, driving foam cell formation, and building vulnerable atherosclerotic plaques.
Elevated homocysteine damages endothelial cells directly, promotes smooth muscle proliferation, and increases thrombotic risk. Homocysteine elevation is linked to B-vitamin deficiency and methylation pathway dysfunction.
Chronic cardiovascular disease is associated with reduced heart rate variability (HRV), reflecting impaired autonomic regulation. Sympathetic dominance increases cardiac workload and arrhythmia risk while reducing recovery capacity.
TREATMENT APPROACH
All protocols are physician-designed and supervised by Dr. Heather Volpp, MD. Therapies are selected based on each patient's evaluation. Results may vary.
EBOO ozone therapy may support cardiovascular health by improving red blood cell deformability and oxygen delivery, reducing oxidative-LDL modification, upregulating endothelial antioxidant defenses, and supporting microcirculatory function.
The HOCATT's far-infrared and carbonic acid combination may support peripheral vasodilation, improve circulation to ischemic tissues, and stimulate parasympathetic nervous system activity beneficial for cardiac patients.
YOUR PATH FORWARD
Every patient begins with a comprehensive physician evaluation. No protocol begins before Dr. Volpp has reviewed your complete clinical picture.
A comprehensive intake with Dr. Volpp reviewing your symptom timeline, prior lab work, medications, and functional status. Targeted lab panels are ordered to identify active biological drivers.
Based on your evaluation findings, Dr. Volpp designs a sequenced treatment protocol — typically combining EBOO sessions, HOCATT therapy, and IV nutrient support at clinically appropriate intervals.
Functional benchmarks and symptom tracking guide protocol adjustments. Follow-up labs assess inflammatory markers and key biomarkers. Treatment frequency is adjusted as you progress toward your goals.
COMMON QUESTIONS
TAKE THE NEXT STEP
Begin with a comprehensive consultation with Dr. Heather Volpp, MD — Board-Certified Internal Medicine. Your evaluation will review your full clinical picture and identify which biological mechanisms may be driving your symptoms.
Book Your Appointment →Physician-Supervised · SynergyO3 Medical · Encinitas, CA · (760) 450-4602
Individual results vary. Consult with Dr. Volpp during your evaluation.
